Landscape and progress of global COVID-19 vaccine development-Reference-Cited by-同舟云学术

Landscape and progress of global COVID-19 vaccine development

Published:2021-07-13 Issue:10 Volume:17 Page:3276-3280
ISSN:2164-5515
Container-title:Human Vaccines & Immunotherapeutics
language:en
Short-container-title:Human Vaccines & Immunotherapeutics

Author:

Huang Hui-Yao¹,Wang Shu-Hang¹,Tang Yu¹,Sheng Wei²,Zuo Chi-Jian³,Wu Da-Wei¹,Fang Hong¹,Du Qiong⁴,Li Ning¹

Affiliation:

1. Department of Clinical Trials Center, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China

2. Departmemt of Medical Affairs, ClinChoice Shanghai Branch, Shanghai, China

3. Department of Research and Development, Suzhou PureCodon Biomedical Technology Co., Ltd

4. Biometrics Department, ClinChoice Shanghai Branch,Shanghai, China

Funder

the Chinese Academy of Medical Sciences’ Initiative for Innovative Medicine

Publisher

Informa UK Limited

Subject

Pharmacology,Immunology,Immunology and Allergy

Link

https://www.tandfonline.com/doi/pdf/10.1080/21645515.2021.1945901

Reference14 articles.

1. U.S. Department of Health and Human Services Food and Drug Administration Center for Biologics Evaluation and Research. Development and licensure of vaccines to prevent COVID-19: guidance for industry. [accessed 2021 April 25]. https://www.fda.gov/media/139638/download.

2. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial

3. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia

4. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine

Cited by 33 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Integrated multi-omics analyses identify anti-viral host factors and pathways controlling SARS-CoV-2 infection;Nature Communications;2024-01-02

2. Immunogenicity of an adenovirus-vectored bivalent vaccine against wild type SARS-CoV-2 and Omicron variants in a murine model;Vaccine;2024-01

3. Autoimmune diseases related to post-SARS-CoV-2 vaccination: A rheumatology perspective;Vacunas (English Edition);2023-10

4. Autoimmune diseases related to post-SARS-CoV-2 vaccination: A rheumatology perspective;Vacunas;2023-10

5. A Comparative Study on Different Approaches of COVID-19 Vaccines;European Journal of Pharmaceutical Research;2023-07-06